Clinical Trial

NMDA Modulation in Major Depressive Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-11-15; most recent amendment 2025-02-16.
Trial Details
NCT Number NCT04637620
Lead Sponsor China Medical University Hospital
Collaborators: Ministry of Science and Technology, Taiwan
Conditions Major Depressive Disorder
Enrollment 90 participants
Start Date 2017-06-01
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-19